Here's Why Gilead Sciences Stock Surged 21% in a Month

Key Takeaways GILD stock rose 20.8% in a month after NEJM published positive phase III ASCENT-04 results in metastatic TNBC.GILD's Trodelvy with Keytruda cut progression or death risk by 35% and lifted median PFS to 11.2 months.GILD data support a new first-line PD-L1 TNBC standard, backing submitted filings to expand Trodelvy's label.Shares of Gilead Sciences, Inc. (GILD) have gained 20.8% in a month compared with the industry’s growth of 4.5%.Much of this rally followed the Jan. 21 announcement that full ...